Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tolvaptan
Drug ID BADD_D02246
Description Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Indications and Usage Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
Marketing Status approved
ATC Code C03XA01
DrugBank ID DB06212
KEGG ID D01213
MeSH ID D000077602
PubChem ID 216237
TTD Drug ID D03KZM
NDC Product Code 31722-869; 59148-088; 60505-4704; 65977-0100; 59148-082; 67877-637; 59148-079; 60505-4318; 60505-4705; 46602-0031; 59148-089; 14501-0066; 31722-868; 59148-083; 46602-0028; 46602-0030; 49884-770; 59148-020; 67877-635; 14501-0085; 57884-0027; 49884-768; 59148-021; 59148-080; 60505-4317; 67877-636; 46602-0027; 46602-0029; 60862-008; 59148-087
UNII 21G72T1950
Synonyms Tolvaptan | 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine | Samsca | OPC 41061 | OPC-41061 | OPC41061
Chemical Information
Molecular Formula C26H25ClN2O3
CAS Registry Number 150683-30-0
SMILES CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000157%
Diabetes insipidus05.03.03.004; 14.05.07.0030.000244%-
Diabetes mellitus05.06.01.001; 14.06.01.0010.000116%-
Diabetic ketoacidosis05.07.03.001; 14.07.03.001---
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Disorientation17.02.05.015; 19.13.01.0020.000256%-
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000145%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.000116%-
Dry eye06.08.02.0010.000157%
Dry mouth07.06.01.0020.000698%
Dry skin23.03.03.001--
Dry throat07.06.01.005; 22.12.03.005---
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.000564%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000058%-
Dysuria20.02.02.0020.000116%
Eating disorder14.03.01.008; 19.09.01.0080.000157%-
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002---
Electrolyte imbalance14.05.01.0020.000058%-
Embolic stroke17.08.01.032; 24.01.04.0100.000058%-
Encephalopathy17.13.02.0010.000145%
Eosinophilia01.02.04.0010.000058%
Eye haemorrhage06.07.02.001; 12.02.02.012; 24.07.05.002---
Failure to thrive14.03.02.008; 18.04.01.003; 19.07.05.0010.000058%-
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Flank pain08.01.08.007; 15.03.04.003; 20.02.03.0060.000116%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages